Date: 2015-01-22
Type of information: Collaboration agreement
Compound: CAR T cell therapy
Company: Kite Pharma (USA - CA) Tel Aviv Sourasky Medical Center (Israel)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On January 22, 2015, Kite Pharma, a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced that the Company has expanded its agreement with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite\'s most advanced programs in cancer immunotherapy. Under the agreement, Kite will collaborate with Professor Zelig Eshhar, Ph.D., the leading pioneer in CAR T cell research and Chair of Immunology Research within the Tel Aviv Sourasky Medical Center\'s Division of Research and Development. Professor Eshhar said, \"Originally, my research had addressed the question of whether T cells can be programmed to effectively recognize and eliminate cancerous cells and to solve the central problem of how and why cancer cells escape the immune system. Now, we believe that we can further enhance this platform technology to develop a whole new generation of CAR T cell products for many tumor types. I look forward to the progress of this program.\"
Financial terms:
Latest news:
